<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy of neuromidin was studied in 62 patients with a small <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and <z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients of the main group received neuromidin as an add-on to basic treatment and patients of the comparison group received only basic treatment (antiaggregant, <z:chebi fb="0" ids="35674">antihypertensive</z:chebi>, cardiac and <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs with the exclusion of nootropic and psychotropic medications) </plain></SENT>
<SENT sid="2" pm="."><plain>The decrease of subjective complaints, improvement of memory, attention, abstract and practical reasoning assessed by neuropsychological tests were seen in 32 patients of the main group after the end of treatment course </plain></SENT>
<SENT sid="3" pm="."><plain>Neuromidin did not cause side-effects and was well tolerated </plain></SENT>
<SENT sid="4" pm="."><plain>The long use of this led to the reduction of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo>, a predictor of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>